Table 2.
The association between use of corticosteroids and 28-day all-cause mortality among patients with COVID-19, according to meta-analysis by REACT working group.
| Treatment (control: usual care or placebo) | Trials included | Patientsenrolled | Number of deaths | Fixed-effect Odds Ratio (95%CI, p-value) | Random-effects Odds Ratio (95%CI, p-value) |
|---|---|---|---|---|---|
| Steroids (Overall) | 7 | 1703 | 647 | 0.66 (95%CI 0.53-0.82; P < 0.01) | 0.70 (95% CI 0.48-1.01; P = 0.05) |
| dexamethasone | 3 | 1282 | 527 | 0.64 (95%CI 0.50-0.82; P <0 .01) | 0.65 (95% CI, 0.36-1.17) |
| hydrocortisone | 3 | 374 | 94 | 0.69 (95% CI 0.43-1.12; P = 0.13) | 0.87 (95%CI, 0.072-10.5) |
| methylprednisolone | 1 | 47 | 26 | 0.91 (95% CI 0.29-2.87; P =0.87) | 0.91 (95%CI, 0.29, 2.87; P = 0.87) |
| low doses of corticosteroids | 4 | 1381 | 472 | 0.61 (95%CI 0.48-0.78; P <0 .01) | 0.80 (95%CI, 0.063-10.32; P = 0.75) |
| high-dose corticosteroids | 3 | 322 | 175 | 0.83 (95%CI 0.53-1.29; P = 0.46) | 0.83 (95%CI, 0.53-1.29; P = 0.46) |